Masimo Corp Rating Reiterated by Zacks (MASI)

Share on StockTwits

Masimo Corp (NASDAQ: MASI)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $23.00 target price on the stock. Zacks‘ price objective would indicate a potential upside of 6.43% from the company’s current price.

A number of other firms have also recently commented on MASI. Analysts at TheStreet upgraded shares of Masimo Corp from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, May 15th. Separately, analysts at Citigroup upgraded shares of Masimo Corp from a “sell” rating to a “neutral” rating in a research note to investors on Friday, May 3rd. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Masimo Corp in a research note to investors on Tuesday, April 9th. They set a “buy” rating on the stock.

One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Masimo Corp currently has an average rating of “Hold” and an average price target of $23.00.

Shares of Masimo Corp (NASDAQ: MASI) traded up 0.46% during mid-day trading on Monday, hitting $21.71. Masimo Corp has a 52 week low of $18.20 and a 52 week high of $25.35. The stock’s 50-day moving average is currently $19.90. The company has a market cap of $1.229 billion and a P/E ratio of 20.01.

Masimo Corp (NASDAQ: MASI) last released its earnings data on Thursday, May 2nd. The company reported $0.28 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.28. The company had revenue of $135.90 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.27 earnings per share. Masimo Corp’s revenue was up 14.0% compared to the same quarter last year. Analysts expect that Masimo Corp will post $1.14 EPS for the current fiscal year.

Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products that improve patient care.

To view Zacks’ full report, visit www.zacks.com

Latest News

McDonald’s Ruling Starts Business Labor Debate
McDonald’s Ruling Starts Business Labor Debate
Millions of Americans Behind on Debt Payments
Millions of Americans Behind on Debt Payments
Stock Futures in U.S. Waiting on Fed and GDP Reports
Stock Futures in U.S. Waiting on Fed and GDP Reports
Fox Increases Cash with Deal Involving BSkyB
Fox Increases Cash with Deal Involving BSkyB
Dunkin’ Brands Earnings Meet Expectations
Dunkin’ Brands Earnings Meet Expectations
Walmart Replaces Top Person in U.S. Business
Walmart Replaces Top Person in U.S. Business


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.